[The effect of fibrinolysis therapy on the survival rate in normotensive hemorrhagic shock].
D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D001778:Blood Coagulation Disorders; D001779:Blood Coagulation Factors / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects; D002675:Child, Preschool; D003911:Dextrans / Q000627:therapeutic use; D004285:Dogs; D004932:Esophageal and Gastric Varices / Q000150:complications; D005260:Female; D005341:Fibrinolysin / Q000627:therapeutic use*; D005342:Fibrinolysis; D005947:Glucose / Q000627:therapeutic use; D006801:Humans; D009638:Norepinephrine / Q000627:therapeutic use; D011516:Prothrombin; D011674:Pulse / Q000187:drug effects; D012771:Shock, Hemorrhagic / Q000188:drug therapy*; D013300:Streptokinase / Q000627:therapeutic use*
D001779:Blood Coagulation Factors; D003911:Dextrans; D011516:Prothrombin; D013300:Streptokinase; D005341:Fibrinolysin; D005947:Glucose; D009638:Norepinephrine
Der Einfluss einer Fibrinolysetherapie auf die Uberlebensquote im normotensiven hämorrhagischen Schock.